UK Markets closed
NIKKEI 225
27,518.25 +41.38 (+0.15%) HANG SENG
19,784.65 +216.96 (+1.11%) CRUDE OIL
73.84 +1.03 (+1.41%) GOLD FUTURES
1,970.40 +16.60 (+0.85%) DOW
32,467.94 +35.86 (+0.11%) BTC-GBP
21,822.65 -201.24 (-0.91%)
Inovio Pharmaceuticals, Inc. (INO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 12:48PM EDT. Market open.
| Previous close | 0.9137 |
| Open | 0.9027 |
| Bid | 0.8611 x 1100 |
| Ask | 0.8639 x 800 |
| Day's range | 0.8000 - 0.9135 |
| 52-week range | 0.8000 - 4.0000 |
| Volume | |
| Avg. volume | 4,453,391 |
| Market cap | 218.527M |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0730 |
| Earnings date | 08 May 2023 - 12 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.33 |
- Motley Fool
Inovio Pharmaceuticals (INO) Q4 2022 Earnings Call Transcript
Good afternoon, and thank you for joining the Inovio 2022 fourth quarter and full year financial results conference call. Joining me on today's call are Dr. Jackie Shea, president and CEO and Dr. Michael Sumner, chief medical officer; and Mr. Today's call will review our corporate and financial information for the quarter and year ended December 31st, 2022, as well as provide an update on our efforts to develop our DNA medicines platform.
- Zacks
Inovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue Estimates
Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Inovio Pharmaceuticals (NASDAQ:INO) adds US$37m to market cap in the past 7 days, though investors from a year ago are still down 69%
Inovio Pharmaceuticals, Inc. ( NASDAQ:INO ) shareholders should be happy to see the share price up 11% in the last...
© 2023 Yahoo. All rights reserved.
